Beelen, D. W. and Trenschel, R. and Casper, J. and Freund, M. and Hilger, R. A. and Scheulen, M. E. and Basara, N. and Fauser, A. A. and Hertenstein, B. and Mylius, H. A. and Baumgart, J. and Pichlmeier, U. and Hahn, Joachim R. and Holler, Ernst (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. BONE MARROW TRANSPLANTATION, 35 (3). pp. 233-241. ISSN 0268-3369,
Full text not available from this repository. (Request a copy)Abstract
Treosulphan has recently demonstrated antileukaemic activity and potent haematopoietic stem cell toxicity. Dose-escalated treosulphan ( 3 x 12 or 3 x 14 g/m(2)) combined with cyclophosphamide (Cy) was chosen for a new preparative regimen before allogeneic haematopoietic stem cell transplantation in 18 patients ( median age 44, range 19 - 64 years) with haematological malignancies, considered ineligible for other myeloablative preparative regimens. Pharmacokinetic studies demonstrated rapid treosulphan plasma clearance and a dose-dependent increase of its maximum plasma concentrations and area under the concentration - time curves. Rapid and sustained white blood cell and platelet recovery and full donor chimerism was attained in all evaluable patients. Non-haematological regimen-related CTC grades 3 - 4 adverse events were transient and predominantly consisted of cardiac (28%), gastrointestinal (39%), and hepatic ( 39%) toxicities. The 1-year nonrelapse mortality was 22%. Principal causes of transplant-related lethal events were infections in three of four affected patients. Only one patient died from regimen-related cardiac toxicity. The 1-year relapse estimate is 22%, overall and progression-free survival estimates are 67 and 56%, respectively. In conclusion, this new treosulphan and Cy combination is an effective, comparatively well-tolerated myeloablative preparative regimen even in patients with an increased risk for regimen-related toxic complications.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW-TRANSPLANTATION; INTRAVENOUS TREOSULFAN; CONDITIONING REGIMEN; SKIN-GRAFTS; TOXICITY; DISEASE; BLOOD; PHARMACOKINETICS; IRRADIATION; RECIPIENTS; treosulphan; transplantation; pharmacokinetic; allogeneic; conditioning |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 28 May 2021 10:36 |
| Last Modified: | 28 May 2021 10:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/36504 |
Actions (login required)
 |
View Item |
